T的拯救：扩大滤泡性淋巴瘤的滤泡T细胞群

IF 44.5 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-08-07 DOI:10.1016/j.ccell.2025.07.016

Teresa Steffen, Dirk Baumjohann

引用次数: 0

摘要

滤泡性淋巴瘤是一种起源于淋巴的富含B细胞的滤泡结构的肿瘤疾病。在这一期的Cancer Cell中，Abe等人使用多组学分析来鉴定和表征不同的滤泡T细胞亚群，这些亚群可用于对滤泡性淋巴瘤的预后进行分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

T’s to the rescue: Expanding the follicular T cell universe in follicular lymphoma

Follicular lymphoma is a neoplastic disease of B cell-rich follicular structures of lymphoid origin. In this issue of Cancer Cell, Abe et al. use multi-omics analyses to identify and characterize distinct follicular T cell subsets that can be used to stratify follicular lymphoma prognoses.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.